Current practices and recommendations of in vitro induction of Cytochrome P450

Abstract

Abstract: Cytochrome P450 (CYP) induction is one of the factors that can affect the pharmacokinetics of a drug molecule upon multiple dosing, and can result in pharmacokinetic drug-drug interactions with coadministered drugs causing potential therapeutic effect change. In recent years, various in vitro assays have been developed and used routinely to assess the potential for drug-drug interactions due to CYP induction, such as nucleolus receptors assay(PXR, AhR, CAR assays) and hepatocyte assays which is more effective. With the data from in vitro assays, we can assess the potential for drug-drug interactions and plan appropriate in vivo and clinical research. This review summaries the currently used models and data interpretation.

Key words: Cytochrome P450, Induction, Assay

CLC Number:

R969.1

SU Jing-hua, SUN Jian-guo, WANG Guang-ji. Current practices and recommendations of in vitro induction of Cytochrome P450[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(8): 954-960.

References

[1] Park JY, Kim KA, Kang MH, et al. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects[J]. Clin Pharmacol Ther, 2004,75(3):157-162.
[2] Rost KL, Brösicke H, Brockmøller J, et al. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl] -caffeine breath test in poor and extensive metabolizers of S-mephenytoin[J]. Clin Pharmacol Ther, 1992,52(2):170-180.
[3] Loboz KK, Gross AS, Williams KM, et al. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity[J]. Clin Pharmacol Ther, 2006, 80(1):75-84.
[4] Jayasagar G, Krishna Kumar M, Chandrasekhar K, et al. Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers[J]. Drug Metabol Drug Interact, 2003,19(4):287-295.
[5] Girre C, Lucas D, Hispard E, et al. Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics[J]. Biochem Pharmacol, 1994, 47(9):1503-1508.
[6] Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study[J]. J Acquir Immune Defic Syndr, 2005, 39(3):307-312.
[7] Niemi M, Backman JT, Neuvonen M, et al. Rifampin decreases the plasma concentrations and effects of repaglinide[J]. Clin Pharmacol Ther, 2000, 68(5):495-500.
[8] M strolinBenedetti, and P Dostert. Induction and autoindaction properties of rifamycin dervatives: a review of animal and human studies [J]. Environ Health Perspest, 1994,102(9):101-105.
[9] Honkakoski P, Sueyoshi T, Negishi M. Drug-activated nuclear receptors CAR and PXR [J].Ann. Med, 2003, 35(3):172-182.
[10] Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation[J]. J Pharm Sci,2005, 94(6):1169-1186.
[11] Kliewer SA,Moore JT,Wade L,et al. An orphan nuclear receptor activated by pregnanes defines a noval steroid signaling pathway[J].Cell, 1998, 92: 73-82.
[12] Xie W,Barwick JL,Downes M,et al. Humanized xenobiotie response in mice expressing nuclear receptor SXR[J].Nature,2000,406:435-439.
[13] 刘艳,尹又,陈尧,等. 人类孕烷受体遗传变异对遗传药理学和药物代谢的影响[J]. 中国临床药理学与治疗学,2007,12(8): 845-849.
[14] Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes[J]. Clin Pharmacokinet,2003, 42(15):1331-1357.
[15] Gao YD, Olson SH, Balkovec JM, et al. Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach[J]. Xenobiotica, 2007, 37(2):124-138.
[16] Zhu Z, Kim S, Chen T, et al. Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays[J]. J Biomol Screen, 2004, 9(6):533-540.
[17] Zhou C, Poulton EJ, Grün F,et al. The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor[J]. Mol Pharmacol, 2007, 71(1):220-229.
[18] Wang H, Li H, Moore LB, et al. The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor[J]. Mol Endocrinol, 2008, 22(4):838-857.
[19] Beischlag TV, Luis Morales J, Hollingshead BD, et al. The aryl hydrocarbon receptor complex and the control of gene expression[J]. Crit Rev Eukaryot Gene Expr, 2008, 18(3):207-250.
[20] Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers[J]. J Pharmacol Exp Ther, 2007, 320(1):72-80.
[21] LeCluyse EL, Alexandre E, Hamilton GA, et al. Isolation and culture of primary human hepatocytes[J]. Methods Mol Biol, 2005, 290:207-229.
[22] Hewitt NJ, Lechon MJ, Houston JB, et al. Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies[J]. Drug Metab Rev, 2007, 39(1):159-234.
[23] Hengsder JG,Utesch D,Steinberg P,et al.Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme indnction[J]. Drug Metab Review, 2000, 32(1): 81.
[24] Roymans D, Annaert P, Van Houdt J, et al. Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes[J]. Drug Metab Dispos,2005, 33:1004-1016.
[25] Harmsen S, Koster AS, Beijnen JH, et al. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction[J]. Drug Metab Dispos, 2008, 36(6):1166-1171.
[26] Gómez-Lechón MJ, Donato T, Jover R,et al. Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2[J]. Eur J Biochem, 2001, 268(5):1448-1459.
[27] Aninat C, Piton A, Glaise D, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells[J]. Drug Metab Dispos, 2006, 34(1):75-83.
[28] Mills JB, Rose KA, Sadagopan N, et al. Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line[J]. J Pharmacol Exp Ther, 2004, 309(1):303-309.
[29] US FDA .Draft Guidance for Industry: Drug interaction studies - study design, data analysis, and implications for dosing and labeling[S]. September 2006.
[30] Sinz M, Kim S, Zhu Z, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions[J]. Curr Drug Metab,2006, 7(4): 375-388.
[31] Hewitt NJ, LeCluyse E, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations[J]. Xenobiotica, 2007, 37(10/11):1196-1224.
[32] Shou M, Hayashi M, Pan Y, et al. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction[J]. Drug Metab Dispos, 2008, 36(11): 2355-2370.
[33] Uno T, Niioka T, Hayakari M, et al. Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations[J]. Eur J Clin Pharmacol, 2007, 63(2):143-149.
[34] Handschin C, Podvinec M, Meyer UA.In silico approaches, and in vitro and in vivo experiments to predict induction of drug metabolism[J]. Drug News Perspect, 2003,16(7):423-434.
[35] Ek M, Soderdahl T, Kuppers-Munther B, et al. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells[J]. Biochem Pharmacol, 2007,74(3):496-503.